csirt@kutim:~/threat-intel/cve/CVE-2026-89620

Katalog CVE

CVSS 7.8 · High EPSS 0,17%

Skor CVSS 3.1 7.8 (High) menurut CNA.

Deskripsi (NVD)

In the Linux kernel, the following vulnerability has been resolved: HID: intel-thc-hid: intel-quickspi: validate report size before copy write_cmd_to_txdma() builds an output report in qsdev->report_buf, a heap buffer allocated in quickspi_alloc_report_buf() to the device-descriptor derived max_report_len (a few hundred bytes for a touch controller). It copies the caller-supplied report into that buffer: memcpy(write_buf->content, report_buf, report_buf_len); The HID core caps a report at HID_MAX_BUFFER_SIZE (16384) by default, and quickspi_hid_ll_driver does not set max_buffer_size, so the length reaches the driver unbounded. A hidraw SET_REPORT/SET_FEATURE ioctl carrying a report larger than max_report_len therefore overflows report_buf with attacker-controlled length and content. Record the report_buf allocation size and reject reports that do not fit before copying, matching the equivalent guard in the intel-quicki2c sibling (quicki2c_init_write_buf()) and the hid-goodix-spi fix. write_cmd_to_txdma() writes the output report header ahead of the content in the same buffer, so size the allocation to cover the header as well. That keeps the added bound from rejecting a maximum-sized report.

Rincian

Terbit di NVD
11 September 2026
Terakhir diubah
13 September 2026
Status NVD
Received
CVSS 3.1
7.8 (High), sumber CNA
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
EPSS (30 hari)
0,17% peluang dieksploitasi; lebih tinggi dari 6,2% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.